Agios Shares Plunge 25% After Novo’s Pill Cuts Crises by 27%
Agios shares plunged 25% after Novo Nordisk’s etavopivat showed a 27% reduction in vaso-occlusive crises and a four-month delay to first crisis, while Agios’ mitapivat failed to meet its primary endpoint. With Novo planning an FDA filing in late 2026, Agios faces steeper competition and reduced commercial prospects for mitapivat.
1. Novo Nordisk Trial Breakthrough
Novo Nordisk’s etavopivat met both primary endpoints in sickle cell disease patients, reducing vaso-occlusive crisis events by 27% versus standard of care and delaying the first crisis by approximately four months.
2. Agios Mitapivat Setback and Stock Impact
Agios’ mitapivat failed to achieve its primary endpoint in a parallel trial, triggering a 25% drop in Agios shares as investors reassess the drug’s accelerated approval prospects and commercial potential.
3. Analyst Perspectives and Regulatory Path
Truist analyst Gregory Renza maintains a buy rating but warns the competitor win widens separation among PK class candidates, while Stifel’s James Condulis notes the outcome is particularly negative for Agios’ accelerated approval ambitions. Agios is now working with the FDA to chart an alternative pathway for mitapivat.